Autoimmune hepatitis: Challenges and novelties
Med Clin (Barc). 2022 Sep 23;159(6):289-298.
doi: 10.1016/j.medcli.2022.04.004.
Epub 2022 Jun 7.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Hepatología, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, España.
- 2 Servicio de Hepatología, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, España. Electronic address: mlondono@clinic.cat.
Abstract
Autoimmune hepatitis is a chronic inflammatory disease of the liver. The etiology is partly unknown and commonly affects women of all ages. It is characterized by increase in transaminase and immunoglobulin G levels, autoantibodies, and portal inflammatory infiltrate with interface hepatitis in the liver biopsy. The treatment is based on the combination of corticoids and azathioprine, but 20-40% of patients require second- or third-line therapies due to intolerance or insufficient response. Here, we will revise the most important aspects regarding the diagnosis and treatment of autoimmune hepatitis emphasizing the challenges faced in clinical practice.
Keywords:
Acute autoimmune hepatitis; Antibodies; Anticuerpos; Autoimmune hepatitis; Daño hepático por fármacos; Drug-induced liver injury; Hepatitis autoinmune; Hepatitis autoinmune aguda; Tratamiento; Treatment.
Copyright © 2022 Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Autoantibodies
-
Azathioprine / therapeutic use
-
Female
-
Hepatitis, Autoimmune* / diagnosis
-
Hepatitis, Autoimmune* / drug therapy
-
Humans
-
Immunoglobulin G / therapeutic use
-
Immunosuppressive Agents / therapeutic use
-
Transaminases / therapeutic use
Substances
-
Autoantibodies
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Transaminases
-
Azathioprine